Optimization of 5-Arylidene Barbiturates As Potent, Selective, Reversible LSD1 Inhibitors for the Treatment of Acute Promyelocytic Leukemia.

Siyuan Xu,Chen Zhou,Rongfeng Liu,Qihua Zhu,Yungen Xu,Fei Lan,Xiaoming Zha
DOI: https://doi.org/10.1016/j.bmc.2018.08.026
IF: 3.461
2018-01-01
Bioorganic & Medicinal Chemistry
Abstract:Histone lysine specific demethylase 1 (LSD1) is overexpressed in diverse hematologic disorders and recognized as a promising target for blood medicines. In this study, molecular docking-based virtual screening united with bioevaluation was utilized to identify novel skeleton of 5-arylidene barbiturate as small-molecule inhibitors of LSD1. Among the synthesized derivatives, 12a exhibited reversible and potent inhibition (IC50 = 0.41 μM) and high selectivity over the MAO-A and MAO-B. Notably, 12a strongly induced differentiation effect on acute promyelocytic leukemia NB4 cell line and distinctly escalated the methylation level on histone 3 lysine 4 (H3K4). Our findings indicate that 5-arylidene barbiturate may represent a new skeleton of LSD1 inhibitors and 12a deserve as a promising agent for the further research.
What problem does this paper attempt to address?